TRENDS

• Drug Formulary Initiatives Moving Beyond Hospitals, Generic Makers Prepping for Regional Lists
  January 30, 2019

• Top 10 PHARMA JAPAN Stories in 2018
  December 26, 2018

• Generic Industry at Crossroads: Companies Face Pressing Need to Boost Profitability ahead of FY2020
  November 28, 2018

• Economic Benefits for Patients, Healthcare Providers Driving Biosimilar Sales Growth as Quality Worries Fade
  November 15, 2018

• Hep C Market Shrinking towards Disease Elimination in 2030
  October 12, 2018

• “Follow-On” Authorized Generics Gaining Ground in Matured Gx Markets; TS-1 Grabs 80% Share
  September 4, 2018

• Strong April-June Sales Show Market Shift to SGLT2/DPP-4 Combos
  August 8, 2018

• As Biosimilars Show Mixed Performances, Lantus Follow-On Is on a Roll
  July 13, 2018

• Japan Drug Makers Downsizing Parent Companies; Takeda Sheds Over 1,000 People in Divestitures, R&D Rejig
  July 3, 2018

• Foreign Players’ Japan Sales Hit Plateau as 11 Firms See Paltry 0.2% Rise; Pfizer, Boehringer Falter
  June 20, 2018

• Drug Maker Downsizing Shows No Sign of Stopping; Boehringer to Ax 300 Jobs, while Shionogi Sees “Tremendous Reduction” in Rep Numbers
  May 31, 2018

• Daiichi Sankyo Espha Sales Double as It Cashes In On Authorized Generic Boom
  May 21, 2018

• Industry Group Anticipates New Demand for Contract Reps after Current Phase of Downsizing by Drug Makers
  April 20, 2018

• Eisai’s Nichi-Iko Deal Marks Watershed in Generic Biz of Research-Driven Makers
  April 3, 2018

• Lilly Japan Joins Top 10 List for 1st Time, Sales Triple in 10 Years on Successive Launches
  March 30, 2018

• Merck Deal Could Pave Way for Eisai to Hit 800 Billion Yen Sales Target in FY2020
  March 13, 2018

• Countering Abilify Cliff, Otsuka Sees New Drug Franchise Set Stage for Growth Path
  February 23, 2018

• With 2 Players Closing in on Suglat, SGLT2 Inhibitors Entering Triangular Battle
  February 8, 2018

• Large Gap in Performance of New Drugs; Products Including Clenafin, Uptravi Doing Well
  November 22, 2017

• 21 Drug Makers Expect 1.6% Increase in Sales but Decline in Profits in FY2017
  November 15, 2017

ページ